Details
Stereochemistry | MIXED |
Molecular Formula | C22H38O5 |
Molecular Weight | 382.5341 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 4 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
InChI
InChIKey=OJLOPKGSLYJEMD-URPKTTJQSA-N
InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
DescriptionSources: http://www.drugbank.ca/drugs/DB00929Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/cdi/misoprostol.html
Sources: http://www.drugbank.ca/drugs/DB00929
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/cdi/misoprostol.html
Misoprostol is a prostaglandin E1 (PGE1) analogue used for the treatment and prevention of stomach ulcers. When administered, misoprostol stimulates increased secretion of the protective mucus that lines the gastrointestinal tract and increases mucosal blood flow, thereby increasing mucosal integrity. It is sometimes co-prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) to prevent the occurrence of gastric ulceration, a common adverse effect of the NSAIDs. Misoprostol seems to inhibit gastric acid secretion by a direct action on the parietal cells through binding to the prostaglandin receptor. The activity of this receptor is mediated by G proteins which normally activate adenylate cyclase. The indirect inhibition of adenylate cyclase by Misoprostol may be dependent on guanosine-5’-triphosphate (GTP). The significant cytoprotective actions of misoprostol are related to several mechanisms. These include: 1. Increased secretion of bicarbonate, 2. Considerable decrease in the volume and pepsin content of the gastric secretions, 3. It prevents harmful agents from disrupting the tight junctions between the epithelial cells which stops the subsequent back diffusion of H+ ions into the gastric mucosa, 4. Increased thickness of mucus layer, 5. Enhanced mucosal blood flow as a result of direct vasodilatation, 6. Stabilization of tissue lysozymes/vascular endothelium, 7. Improvement of mucosal regeneration capacity, and 8. Replacement of prostaglandins that have been depleted as a result of various insults to the area. Misoprostol has also been shown to increase the amplitude and frequency of uterine contractions during pregnancy via selective binding to the EP-2/EP-3 prostanoid receptors. Misoprostol is indicated for the treatment of ulceration (duodenal, gastric and NSAID induced) and prophylaxis for NSAID induced ulceration. Misoprostol is also indicated for other uses that are not approved in Canada, including the medical termination of an intrauterine pregnancy used alone or in combination with methotrexate, as well as the induction of labour in a selected population of pregnant women with unfavourable cervices. This indication is avoided in women with prior uterine surgery or cesarean surgery due to an increased risk of possible uterine rupture. Misoprostol is also used for the prevention or treatment of serious postpartum hemorrhage. Misoprostol is sold under the brandname Cytotec among others.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1881 Sources: http://www.drugbank.ca/drugs/DB00929 |
3.74 µM [EC50] | ||
Target ID: CHEMBL3710 Sources: http://www.drugbank.ca/drugs/DB00929 |
124.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Cytotec Approved UseCytotec (misoprostol) is indicated for reducing the risk of NSAID (nonsteroidal antiinflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant
debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Launch Date5.9909761E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.683 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27102981 |
800 μg single, oral dose: 800 μg route of administration: Oral experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1.361 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27102981 |
800 μg single, buccal dose: 800 μg route of administration: Buccal experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.439 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27102981 |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
811 pg/mL |
300 μg single, oral dose: 300 μg route of administration: Oral experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.019 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27102981 |
800 μg single, oral dose: 800 μg route of administration: Oral experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.073 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27102981 |
800 μg single, buccal dose: 800 μg route of administration: Buccal experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
3.209 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27102981 |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
417 pg × h/mL |
300 μg single, oral dose: 300 μg route of administration: Oral experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27102981 |
800 μg single, oral dose: 800 μg route of administration: Oral experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
0.837 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27102981 |
800 μg single, buccal dose: 800 μg route of administration: Buccal experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
0.854 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27102981 |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
0.5 h |
300 μg single, oral dose: 300 μg route of administration: Oral experiment type: SINGLE co-administered: |
MISOPROSTOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% |
MISOPROSTOL serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
12 mg single, oral Overdose |
healthy, adolescent n = 1 Health Status: healthy Condition: induce abortion Age Group: adolescent Sex: F Population Size: 1 Sources: |
Disc. AE: Multiorgan failure... AEs leading to discontinuation/dose reduction: Multiorgan failure (grade 5, 1 patient) Sources: |
8400 mg single, oral Overdose Dose: 8400 mg Route: oral Route: single Dose: 8400 mg Sources: |
healthy, mean 28.8 years n = 1 Health Status: healthy Condition: induce abortion Age Group: mean 28.8 years Sex: F Population Size: 1 Sources: |
Disc. AE: Abdominal pain, Vomiting... AEs leading to discontinuation/dose reduction: Abdominal pain (1 patient) Sources: Vomiting (1 patient) Diarrhea (1 patient) |
50 ug 4 times / day steady, vaginal Recommended Dose: 50 ug, 4 times / day Route: vaginal Route: steady Dose: 50 ug, 4 times / day Sources: |
healthy, mean 28.8 years n = 172 Health Status: healthy Condition: live term single cephalic fetus for indicated labor induction Age Group: mean 28.8 years Sex: F Population Size: 172 Sources: |
Other AEs: Diarrhea, Nausea... Other AEs: Diarrhea (1.7%) Sources: Nausea (9.3%) Vomiting (14%) |
50 ug 6 times / day steady, oral Recommended Dose: 50 ug, 6 times / day Route: oral Route: steady Dose: 50 ug, 6 times / day Sources: |
healthy, mean 29.1 years n = 167 Health Status: healthy Condition: live term single cephalic fetus for indicated labor induction Age Group: mean 29.1 years Sex: F Population Size: 167 Sources: |
Other AEs: Nausea, Vomiting... |
400 ug single, oral Dose: 400 ug Route: oral Route: single Dose: 400 ug Co-administed with:: mifepristone(600 mg) Sources: |
healthy, mean 30.2 years n = 92 Health Status: healthy Condition: induce abortion Age Group: mean 30.2 years Sex: F Population Size: 92 Sources: |
Other AEs: Bleeding, Vomiting... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Multiorgan failure | grade 5, 1 patient Disc. AE |
12 mg single, oral Overdose |
healthy, adolescent n = 1 Health Status: healthy Condition: induce abortion Age Group: adolescent Sex: F Population Size: 1 Sources: |
Abdominal pain | 1 patient Disc. AE |
8400 mg single, oral Overdose Dose: 8400 mg Route: oral Route: single Dose: 8400 mg Sources: |
healthy, mean 28.8 years n = 1 Health Status: healthy Condition: induce abortion Age Group: mean 28.8 years Sex: F Population Size: 1 Sources: |
Diarrhea | 1 patient Disc. AE |
8400 mg single, oral Overdose Dose: 8400 mg Route: oral Route: single Dose: 8400 mg Sources: |
healthy, mean 28.8 years n = 1 Health Status: healthy Condition: induce abortion Age Group: mean 28.8 years Sex: F Population Size: 1 Sources: |
Vomiting | 1 patient Disc. AE |
8400 mg single, oral Overdose Dose: 8400 mg Route: oral Route: single Dose: 8400 mg Sources: |
healthy, mean 28.8 years n = 1 Health Status: healthy Condition: induce abortion Age Group: mean 28.8 years Sex: F Population Size: 1 Sources: |
Diarrhea | 1.7% | 50 ug 4 times / day steady, vaginal Recommended Dose: 50 ug, 4 times / day Route: vaginal Route: steady Dose: 50 ug, 4 times / day Sources: |
healthy, mean 28.8 years n = 172 Health Status: healthy Condition: live term single cephalic fetus for indicated labor induction Age Group: mean 28.8 years Sex: F Population Size: 172 Sources: |
Vomiting | 14% | 50 ug 4 times / day steady, vaginal Recommended Dose: 50 ug, 4 times / day Route: vaginal Route: steady Dose: 50 ug, 4 times / day Sources: |
healthy, mean 28.8 years n = 172 Health Status: healthy Condition: live term single cephalic fetus for indicated labor induction Age Group: mean 28.8 years Sex: F Population Size: 172 Sources: |
Nausea | 9.3% | 50 ug 4 times / day steady, vaginal Recommended Dose: 50 ug, 4 times / day Route: vaginal Route: steady Dose: 50 ug, 4 times / day Sources: |
healthy, mean 28.8 years n = 172 Health Status: healthy Condition: live term single cephalic fetus for indicated labor induction Age Group: mean 28.8 years Sex: F Population Size: 172 Sources: |
Vomiting | 17.4% | 50 ug 6 times / day steady, oral Recommended Dose: 50 ug, 6 times / day Route: oral Route: steady Dose: 50 ug, 6 times / day Sources: |
healthy, mean 29.1 years n = 167 Health Status: healthy Condition: live term single cephalic fetus for indicated labor induction Age Group: mean 29.1 years Sex: F Population Size: 167 Sources: |
Nausea | 9.6% | 50 ug 6 times / day steady, oral Recommended Dose: 50 ug, 6 times / day Route: oral Route: steady Dose: 50 ug, 6 times / day Sources: |
healthy, mean 29.1 years n = 167 Health Status: healthy Condition: live term single cephalic fetus for indicated labor induction Age Group: mean 29.1 years Sex: F Population Size: 167 Sources: |
Bleeding | 68.2% | 400 ug single, oral Dose: 400 ug Route: oral Route: single Dose: 400 ug Co-administed with:: mifepristone(600 mg) Sources: |
healthy, mean 30.2 years n = 92 Health Status: healthy Condition: induce abortion Age Group: mean 30.2 years Sex: F Population Size: 92 Sources: |
Vomiting | 7.6% | 400 ug single, oral Dose: 400 ug Route: oral Route: single Dose: 400 ug Co-administed with:: mifepristone(600 mg) Sources: |
healthy, mean 30.2 years n = 92 Health Status: healthy Condition: induce abortion Age Group: mean 30.2 years Sex: F Population Size: 92 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Misoprostol in the treatment of duodenal ulcer. A multicenter double-blind placebo-controlled study. | 1985 Nov |
|
Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. | 1986 Aug |
|
The effect of misoprostol on base-line and stimulated acid secretion and on gastrin and histamine release in the totally isolated, vascularly perfused rat stomach. | 1988 Aug |
|
Neurosensory adverse effects after phenylbutazone and misoprostol combined treatment. | 1989 Nov 25 |
|
Neurological adverse effects of naproxen and misoprostol combination. | 1990 Oct |
|
H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment. | 1991 |
|
Overall safety of Arthrotec. | 1992 |
|
Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. | 1992 Dec |
|
Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. | 1993 Aug 1 |
|
RU486: the French experience. | 1994 Jun |
|
Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients. | 1995 Apr |
|
The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis. | 1995 Jul |
|
Misoprostol associated autonomic dysreflexia in a traumatic tetraplegic patient. | 1996 Feb |
|
Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. | 1997 Sep |
|
Use of misoprostol during pregnancy and Möbius' syndrome in infants. | 1998 Jun 25 |
|
Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. | 2000 Dec 11 |
|
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. | 2000 Jan 17 |
|
High rates of cramping with misoprostol administration for intrauterine insemination. | 2001 May |
|
Cognitive decline in administration of the nonsteroidal antiinflammatory drug loxoprofen with misoprostol in a 91-year-old Japanese woman. | 2002 Oct |
|
Effect of misoprostol and indomethacin on cyclooxygenase induction and eicosanoid production in carrageenan-induced air pouch inflammation in rats. | 2002 Sep |
|
[Moebius syndrome due to the use of misoprostol. Case report]. | 2003 Jun |
|
Poland-Möbius syndrome and cocaine abuse: a relook at vascular etiology. | 2005 Apr |
|
Prostaglandin analogue misoprostol attenuates neurotoxin 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death in differentiated PC12 cells. | 2008 Nov 25 |
|
Protective effect of anacardic acids from cashew (Anacardium occidentale) on ethanol-induced gastric damage in mice. | 2010 Jan 5 |
|
Moebius syndrome and holoprosencephaly following exposure to misoprostol. | 2010 Nov |
|
Effects of misoprostol on cisplatin-induced renal damage in rats. | 2011 Jul |
|
Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors. | 2011 Jul 28 |
Patents
Sample Use Guides
The recommended adult oral dose of Cytotec (Misoprostol) for reducing the risk of NSAID-induced gastric ulcers is 200 mcg four times daily with food. If this dose cannot be tolerated, a dose of 100 mcg can be used
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10357877
Antigen-evoked secretion of IFN-gamma by influenza hemagglutinin-specific mouse lymph node Th1 cells, that also express EP3Rs and EP4Rs, was increased a maximum of 10-fold by 10(-9) M misoprostol.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000007710
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
WHO-ATC |
G02AD06
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
22.1 (MIF/MIS)
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
NDF-RT |
N0000007710
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
WHO-ATC |
A02BB01
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
LIVERTOX |
644
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
NDF-RT |
N0000175785
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
NCI_THESAURUS |
C2080
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
WHO-VATC |
QA02BB01
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
FDA ORPHAN DRUG |
186604
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
NCI_THESAURUS |
C29701
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
WHO-VATC |
QM01AE56
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
NDF-RT |
N0000007710
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
NCI_THESAURUS |
C78568
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
WHO-ATC |
M01AE56
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
WHO-VATC |
QG02AD06
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
22.1
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C1313
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
SUB08998MIG
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
Misoprostol
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
D016595
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
m7563
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | Merck Index | ||
|
1444300
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
0E43V0BB57
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
1817
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
3573
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
5154
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
1936
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
MISOPROSTOL
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
42331
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | RxNorm | ||
|
5282381
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
DB00929
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
59122-46-2
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
100000092418
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
63610
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
CHEMBL606
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
0E43V0BB57
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY | |||
|
DTXSID7020897
Created by
admin on Fri Dec 15 15:38:17 UTC 2023 , Edited by admin on Fri Dec 15 15:38:17 UTC 2023
|
PRIMARY |
METABOLITE ACTIVE (PRODRUG)
SUBSTANCE RECORD